Evaluation of 4-factor prothrombin complex concentrate (PCC) in hospitalized patients by Waters, Kacie & George, Mary
   
 
       
              
            
         
 
 
 
 
 
 
 
             
               
           
 
    
       
      
         
          
     
 
   
              
           
   
 
    
             
           
   
              
            
     
 
   
             
          
    
 
      
           
           
        
 
      
            
               
              
            
       
 
   
           
    
 
   
            
         
             
             
              
            
             
       
 
        
          
   
                  
        
     
     
  
 
       
          
         
   
 
           
         
         
       
 
           
 
 
      
 
 
  
 
    
              
       
      
 
    
             
            
           
             
       
 
              
  
 
 
 
 
    
               
              
              
               
            
 
             
 
 
   
            
           
            
          
     
 
 
 
 
 
 
 
   
              
     
  
  
 
 
 
 
 
 
RESEARCH POSTER PRESENTATION DESIGN © 2015 
www.PosterPresentations.com 
This study was approved by the study institution’s 
Institutional Review Board.   
 Inclusion criteria: 
o All patients who received 4-factor PCC at the 
study institution  
 Dates:  
o October 1, 2014 to October 28, 2015.   
A retrospective chart review was performed on 
these patients to complete the evaluation.  Patients 
were followed until discharge 
• Data collected 
o Patient demographics (sex, age, weight, IBW, 
BMI, height, and serum creatinine prior to 
PCC administration) 
o Ordering physician discipline 
o Drug reversed or indication for PCC 
o Location of bleed 
o Dose administered 
o Baseline and follow up INR, PTT, and PT as 
appropriate,  
o Other factors or blood products utilized 
o Surgical and procedural interventions 
required 
o Patient disposition 
Patients were followed until discharge.  Creatinine 
clearance was calculated using Cockcroft-Gault 
equation.  This data was evaluated as appropriate or 
non-appropriate based on the study institution’s 
developed protocol for anticoagulant reversal.   
In 2014, the study institution developed reversal 
guidelines to assist physicians in selection of 
reversal agents for all available oral and parenteral 
anticoagulants.   
 Primary objective:  
o To evaluate whether 4-factor PCC usage was 
appropriately designated and dosed for 
patients experiencing acute bleeds or 
preparing for invasive procedures  
 Secondary objectives:   
o To examine the proportion of 4-factor PCC 
use on warfarin associated bleeds versus other 
various oral anticoagulants.   
o To evaluate the effect of 4-factor PCC on 
bleeding and the effect on INR, PTT, and PT 
reduction.  
Purpose 
Methods 
A report was generated of patients who have received PCC between October 1, 2014 to October 28, 2015. 
 N = 36 
o Males: 58% (n=21) 
o Females: 42% (n=15) 
 Average age: 71.2 years (Range: 30 – 95) 
o Age <65 years: 25% (n=9) 
o Age 65-75 years: 30.6% (n=11) 
o Age  >75 years: 44.4% (n=16) 
  Average Weight (kg): 86.9 (Range: 48.5 – 141.5) 
o Weight <60 kg: 5.6% (n=2) 
 Patients with active bleeding: 91.7% (n=33) 
Results Conclusions 
Based on these results, we conclude that 4-factor 
PCC was appropriately indicated in 91.7% of the 
cases between the dates of October 1, 2014 to 
October 28, 2015.   
 It is not indicated for:  
o Warfarin toxicity in the absence of bleeding  
o Reversal of enoxaparin  
PCC was correctly dosed in 83.3% of total patients 
included in the review. 
 Correct dose by drug: 
o 81.8% of warfarin reversals 
o 90% of rivaroxaban reversals 
o 100% of dabigatran reversals 
o 100% of apixaban reversals 
 4-factor PCC was mostly used for reversal of 
warfarin 
 28% of cases involved  NOACs   
 Comparison of baseline, follow-up, and average 
levels show a large improvement in INR for 
warfarin 
o Minimal changes in PT and PTT for  
rivaroxaban, dabigatran, and apixaban.   
 The overall mortality rate among patients 
receiving 4-factor PCC in our sample was 28%. 
 No thrombotic events occurred as a result of 
administration of PCC.   
Overall, we conclude 4-factor PCC is being used 
appropriately according to the protocol in 78% of 
patients in the the institution based on correct 
indication and dosing.   
Education may be needed on  choosing correct 
dosages for warfarin reversal in life-threatening 
bleeds based on patient’s INR.  We also recommend 
adding reversal agents for each individual NOAC 
for appropriate indications as they become FDA 
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Warfarin NOACs Trauma Enoxaparin 
Yes 18 9 3 0 
No 4 1 0 1 
Percent Correct 81.8% 90% 100% 0% 
Warfarin Rivaroxaban Dabigatran Apixaban Trauma Overall 
27% 20% 0% 33% 66.7% 28% 
Table 2.  Mortality Rate Among Each Indication for PCC  
Figure 3.  Comparison of  Baseline and Follow Up INR, PT, and PTT Levels 
Table 1.  Number of Correct Doses Per Protocol  
Figure 1.  4-Factor PCC Indications 
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Figure 2.  Comparison of Sites of Bleeds 
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